Meglumine
Also known as: Dimeglumine
Meglumine Antimoniate is used for many diagnostic test in different concentrations such as 85% injection is used for adult angiocardiography and thoracic aortography and a 76% solution is used in excretion urography, paediatric angiocardiography and Meglumine Diatrizoate, Sodium and Sodium Meglumine is used for angiocardiography and thoracic aortography in different concentrations. Meglumine Iodoxamate is the methylglucamine salt of an ionic, water-soluble, dimeric, radiographic contrast medium; formerly used primarily for intravenous cholangiography.
Primary Characteristics
Meglumine is also known as Dimeglumine, Meglumine gadopentetate, Meglumine Antimoniate, Meglumine Diatrizoate, Sodium and Sodium Meglumine, Meglumine Iodoxamate, Meglumine Iotroxate.
It is of Synthetic origin and belongs to Methylglucamine sodium.
It is classified in Diagnostic Aids , Antiprotozoal pharmacological group. It is also classified under Radiopaque Agents .
Molecular Weight: 195.2 · Solubility in Water: Slightly soluble · Solubility in Alcohol: Sparingly soluble · Non-proprietary name: Meglumine · pH: 7.9 · Isotonic value: 10.55.
Pharmacokinetics
Absorption: Meglumine has an oral bioavailability is 1% (±1%).
Distribution: Meglumine has a volume of distribution is 19.5% body weight. plasma protein binding is < 5%.
Elimination: plasma half-life is 1.666 hr, renal excretion is 95%.
Advertisement
Indications
Meglumine is primarily indicated in conditions like Angiography, Arthrography, Cholangiography, Cholecystography, CT enhancement, Cutaneous leishmaniasis, Duodenal ulcer associated with h. Pylori, Excretion urography, Radiological contrast agent, Splenoportography, Venography.
Contraindications
Meglumine is contraindicated in conditions like Acidosis, Asthma, Phaeochromocytoma, Thyrotoxicosis, Sickle cell anaemia, Cardiac insufficiency, Congestive heart failure, Myeloma, Pulmonary edema, Impaired renal function, Intracranial hemorrhage, Atopy, Dehydration, Inadequate urine flow, Sickle cell disease, Hypersensitivity to the drug, Hypothyroidism.
Dosage
Meglumine's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 0 – 0 | — | — | Consult your physcian. | |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Meglumine in overdosage may give rise to further complications which include Pancreatitis , Impaired renal function , Hyperthyroidism .
Meglumine produces potentially life-threatening effects which include Anaphylactoid reactions , Ventricular fibrillation, Pulmonary edema , Cardiac arrhythmias, Angioneurotic edema. Careful monitoring is needed with proper medical management.
The signs and symptoms that are produced after acute overdosage of Meglumine are Bradycardia, Hypotension, Anaphylactoid reactions, Pyrexia, Renal failure, Tremor.
Meglumine is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Altered taste sensations, Chills, Colitis, Diarrhea, Dizziness, Enteritis , Faintness , Fever, Flushing, Headache, Hypertension , Hypotension , Itching, Muscle weakness, Nausea, Nausea and vomiting, Nodular goitre, Rashes , Sneezing, Urticaria, Vomiting .
Warnings / Precautions
Interference in Pathology
Meglumine may interfere in the diagnosis of Thyroid Function Test , Sulphosalicylic acid test for urinary protein. , Falsely alkaptonuria results with cupric sulphate urinary glucose test. .
Available Brands
Storage Conditions
Drug Classification
- 1.6.4.2 — Antileishmanial drugs
- 2.14.2 — Radiocontrast media